NCT06692933 Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
| NCT ID | NCT06692933 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Washington State University |
| Condition | Interaction |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2024-06-20 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2024-06-20 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.
Eligibility Criteria
Inclusion Criteria: * 21-64 years old and healthy; * Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer; * Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel; * Have taken hemp or cannabis (in any form) before and tolerated it well; * Willing to abstain from consuming dietary supplements/botanical products and citrus juices for the duration of the study; * Willing to abstain from cannabis/marijuana, hemp, THC- and/or CBD-containing products for several weeks; * Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day; * Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day; * Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study; * Have the ability to and are willing to comply with the requirements of the study; * Geographically located within a 40-mile radius of Spokane and have the time to participate and; * Can read and speak English Exclusion Criteria: * Under the age of 21 or over the age of 64; * Any major illness; * Pregnant or nursing; * History of allergy or intolerance to cannabis or clopidogrel; * Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel; * Never taken cannabis (in any form) before; * Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data; * Currently using or have recently used drugs or other illicit substances for recreational purposes; * Have used cannabis/marijuana, hemp, THC- and/or CBD-containing products within the last 4 weeks; * Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or; * Unable to read and speak English
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06692933 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 64 Years, studying Interaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06692933 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06692933 currently recruiting?
Yes, NCT06692933 is actively recruiting participants. Contact the research team at mary.paine@wsu.edu for enrollment information.
Where is the NCT06692933 trial being conducted?
This trial is being conducted at Spokane, United States.
Who is sponsoring the NCT06692933 clinical trial?
NCT06692933 is sponsored by Washington State University. The trial plans to enroll 24 participants.